Physician profile
Rodney Keel
NPI 1740712835
$4,186.75
in general payments reported to CMS, 2019-2025
16 companies · $556 in 2025
The $556 reported for 2025 was more than what 80% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,358 · 2024: $1,273 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,186.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $679.61 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Corium, LLC | $620.56 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $561.16 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $383.36 | 2023-2025 | Auvelity |
| Neos Therapeutics, Lp | $358.27 | 2023-2025 | Adzenys Xr-Odt |
| Abbvie INC. | $355.22 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $283.32 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $199.16 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $174.84 | 2023-2024 | Quviviq |
| Lundbeck LLC | $154.91 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $131.81 | 2023-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $111.56 | 2023-2024 | Jornay Pm |
| Almatica Pharma LLC | $105.58 | 2023-2024 | Loreev Xr, Teriparatide, Gralise |
| Indivior INC. | $37.17 | 2024 | Sublocade |
| Collegium Pharmaceutical, INC. | $15.71 | 2025 | Jornay Pm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $14.51 | 2023 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Keel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.